Imaging methodology across complex therapeutic areas.
In many trials imaging is not just a diagnostic tool — it is a regulatory endpoint, a surrogate biomarker and a driver of clinical decision-making.
Dixit supports sponsors and CROs in the strategic integration of imaging into their studies, applying the standardisation, reproducibility and methodological control each therapeutic area demands.
Three areas, one methodological standard.
Each area carries its own endpoints, response criteria and sources of variability. We bring the same discipline to all of them — from imaging charter to independent central review and traceable archive.
Oncology
Tumour response, progression and functional biomarkers under RECIST and beyond.
Explore oncologyHaematology
Imaging support for lymphoma and haematological malignancy response assessment.
Explore haematologyMolecular imaging & theranostics
Molecular imaging, biodistribution and dosimetry for radiopharmaceutical studies.
Explore theranosticsIntegrate imaging into your therapeutic programme.
Tell us about your indication, endpoints and response criteria. Our imaging scientists will map the methodology that keeps every read consistent, reproducible and inspection-ready.